Jane Tian

6.8k citations
37 papers · 3.8k indexed · 1 hit paper · h-index 28

Jane Tian

37 papers receiving 3.8k citations

Hit Papers

Tim-3 inhibits T helper type 1–mediated auto- and alloimm...6012003202620102018200400600

Peers

Jane Tian
Comparison fields: 5 of 101
  • Immunology 2.3k
  • Ophthalmology 256
  • Immunology and Allergy 166
  • Cancer Research 375
  • Oncology 659
Replace Shyr‐Te Ju with:
Shyr‐Te Ju United States
Suofu Qin United States
Silvia Montaner United States
Roland Tisch United States
Rie Watanabe‐Fukunaga Japan
S. Frieda A. Pearce United States
Charles E. Egwuagu United States
Byungsuk Kwon South Korea
Hui Shao United States
Xiaodong Yang China
Jane Tian relative to Shyr‐Te Ju United States Shyr‐Te Ju's profile →
Citations per field
00.5×
Shyr‐Te Ju · 1×
Citations per year

Countries citing papers authored by Jane Tian

Since Specialization
Citations

This map shows the geographic impact of Jane Tian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Tian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Tian more than expected).

Fields of papers citing papers by Jane Tian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Tian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Tian. The network helps show where Jane Tian may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jane Tian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jane Tian Line = papers co-authored together Jane Tian links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20251
2 202116
3 202039
4 201782
5 201778
6 201683
7 2014118
8 201350
9 201028
10 200959
11 200948
12 200882
13 200690
14 20053
15 2004202
16 200434
17 2003185
18 200149
19 2000251
20 1999312

About Jane Tian

Jane Tian is a scholar working on Immunology, Clinical Biochemistry and Ophthalmology, having authored 37 papers that have together received 3.8k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (10 papers), Retinal Diseases and Treatments (5 papers), Immune Response and Inflammation (5 papers), DNA Repair Mechanisms (4 papers), Mitochondrial Function and Pathology (4 papers), NF-κB Signaling Pathways (4 papers), IL-33, ST2, and ILC Pathways (3 papers) and Retinal Development and Disorders (3 papers). The work is most often cited by research in Immunology (2.3k citations), Ophthalmology (256 citations) and Immunology and Allergy (166 citations). Jane Tian has collaborated with scholars based in United States, Germany and Denmark. Frequent co-authors include Anthony J. Coyle, Tracy Delaney, Clare M. Lloyd, José-Carlos Gutierrez-Ramos, José Carlos Gutierrez‐Ramos, James T. Handa, Thomas Kamradt, Trang Nguyen, Vilhelm A. Bohr and Deborah L. Croteau. Their work appears in journals such as Immunity, The Journal of Immunology, Nature Communications, The Journal of Experimental Medicine and Nature Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026